AbbVie Inc. $ABBV Stake Trimmed by Quadrant Capital Group LLC

Quadrant Capital Group LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,708 shares of the company’s stock after selling 522 shares during the period. Quadrant Capital Group LLC’s holdings in AbbVie were worth $9,784,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Marshall & Sullivan Inc. WA purchased a new position in AbbVie during the 2nd quarter worth approximately $25,000. TD Capital Management LLC raised its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the 2nd quarter worth about $36,000. Finally, Bear Mountain Capital Inc. grew its stake in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research reports. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Citigroup reduced their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Evercore ISI upped their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. Finally, Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $241.85.

AbbVie Trading Down 1.8%

Shares of ABBV stock opened at $227.57 on Thursday. The business’s 50 day moving average is $227.51 and its two-hundred day moving average is $206.27. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a market cap of $402.20 billion, a PE ratio of 108.37, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.